(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone dihydrate and methods of its use
View Patent ↗(E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate, compositions comprising it, and methods of its use are disclosed.
1. Crystalline (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate having an XRPD pattern with peaks at about 12.5, 14.1, 16.9, 20.4, 25.2 and/or 27.0 degrees 2θ when obtained using copper Kα radiation.
2. A composition comprising crystalline (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate and a pharmaceutically acceptable excipient.
3. A pharmaceutical dosage form suitable for administration to a patient comprising the composition of claim 2 .
4. The pharmaceutical dosage form of claim 3 , which is suitable for oral administration to a patient.
5. The pharmaceutical dosage form of claim 4 , which is a capsule.
6. The pharmaceutical dosage form of claim 4 , which is a tablet.
7. The pharmaceutical dosage form of claim 3 , which is suitable for topical administration to a patient.
8. The pharmaceutical dosage form of claim 3 , which is suitable for transdermal administration to a patient.
9. The pharmaceutical dosage form of claim 8 , which is a patch.
10. (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate, which is a solid.
11. A composition comprising a pharmaceutically acceptable excipient and the (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate of claim 10 .